Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Plasma proteins predict conversion to dementia from prodromal disease.

Hye A, Riddoch-Contreras J, Baird AL, Ashton NJ, Bazenet C, Leung R, Westman E, Simmons A, Dobson R, Sattlecker M, Lupton M, Lunnon K, Keohane A, Ward M, Pike I, Zucht HD, Pepin D, Zheng W, Tunnicliffe A, Richardson J, Gauthier S, Soininen H, Kłoszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S.

Alzheimers Dement. 2014 Nov;10(6):799-807.e2. doi: 10.1016/j.jalz.2014.05.1749. Epub 2014 Jul 8.

2.

Framingham Risk Score and the Risk of Progression from Mild Cognitive Impairment to Dementia.

Viticchi G, Falsetti L, Buratti L, Sajeva G, Luzzi S, Bartolini M, Provinciali L, Silvestrini M.

J Alzheimers Dis. 2017;59(1):67-75. doi: 10.3233/JAD-170160.

PMID:
28582863
3.

Predicting Progression from Mild Cognitive Impairment to Alzheimer's Dementia Using Clinical, MRI, and Plasma Biomarkers via Probabilistic Pattern Classification.

Korolev IO, Symonds LL, Bozoki AC; Alzheimer's Disease Neuroimaging Initiative.

PLoS One. 2016 Feb 22;11(2):e0138866. doi: 10.1371/journal.pone.0138866. eCollection 2016.

4.

Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.

Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Handels R, L'Italien G, van der Flier W, Aalten P, Teunissen C, Barkhof F, Blennow K, Wolz R, Rueckert D, Verhey F, Visser PJ.

Neurobiol Aging. 2012 Oct;33(10):2272-81. doi: 10.1016/j.neurobiolaging.2011.12.017. Epub 2012 Jan 20.

PMID:
22264648
5.

Combinatorial markers of mild cognitive impairment conversion to Alzheimer's disease--cytokines and MRI measures together predict disease progression.

Furney SJ, Kronenberg D, Simmons A, Güntert A, Dobson RJ, Proitsi P, Wahlund LO, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Spenger C, Lovestone S.

J Alzheimers Dis. 2011;26 Suppl 3:395-405. doi: 10.3233/JAD-2011-0044.

PMID:
21971479
6.

Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.

Da X, Toledo JB, Zee J, Wolk DA, Xie SX, Ou Y, Shacklett A, Parmpi P, Shaw L, Trojanowski JQ, Davatzikos C; Alzheimer's Neuroimaging Initiative.

Neuroimage Clin. 2013 Nov 28;4:164-73. doi: 10.1016/j.nicl.2013.11.010. eCollection 2014.

7.

Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment.

Babić Leko M, Borovečki F, Dejanović N, Hof PR, Šimić G.

J Alzheimers Dis. 2016;50(3):765-78. doi: 10.3233/JAD-150705.

PMID:
26836160
8.

Role of cerebrospinal fluid biomarkers to predict conversion to dementia in patients with mild cognitive impairment: a clinical cohort study.

Tondelli M, Bedin R, Chiari A, Molinari MA, Bonifacio G, Lelli N, Trenti T, Nichelli P.

Clin Chem Lab Med. 2015 Feb;53(3):453-60. doi: 10.1515/cclm-2014-0414.

PMID:
25274948
9.

Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Ritchie C, Smailagic N, Noel-Storr AH, Takwoingi Y, Flicker L, Mason SE, McShane R.

Cochrane Database Syst Rev. 2014 Jun 10;(6):CD008782. doi: 10.1002/14651858.CD008782.pub4. Review.

PMID:
24913723
10.

Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia.

Targosz-Gajniak MG, Siuda JS, Wicher MM, Banasik TJ, Bujak MA, Augusciak-Duma AM, Opala G.

J Neurol Sci. 2013 Dec 15;335(1-2):58-63. doi: 10.1016/j.jns.2013.08.023. Epub 2013 Aug 27.

PMID:
24035276
11.

Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.

Dukart J, Sambataro F, Bertolino A.

J Alzheimers Dis. 2016;49(4):1143-59. doi: 10.3233/JAD-150570.

PMID:
26599054
12.

Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.

Yu P, Dean RA, Hall SD, Qi Y, Sethuraman G, Willis BA, Siemers ER, Martenyi F, Tauscher JT, Schwarz AJ.

J Alzheimers Dis. 2012;32(2):373-85. doi: 10.3233/JAD-2012-120832.

PMID:
22796873
13.

CERAD neuropsychological compound scores are accurate in detecting prodromal alzheimer's disease: a prospective AddNeuroMed study.

Paajanen T, Hänninen T, Tunnard C, Hallikainen M, Mecocci P, Sobow T, Tsolaki M, Vellas B, Lovestone S, Soininen H.

J Alzheimers Dis. 2014;39(3):679-90. doi: 10.3233/JAD-122110.

PMID:
24246420
14.

Predicting progression to dementia in elderly subjects with mild cognitive impairment using both cognitive and neuroimaging predictors.

Peters F, Villeneuve S, Belleville S.

J Alzheimers Dis. 2014;38(2):307-18. doi: 10.3233/JAD-130842.

PMID:
23963293
15.

Generalizability of the disease state index prediction model for identifying patients progressing from mild cognitive impairment to Alzheimer's disease.

Hall A, Muñoz-Ruiz M, Mattila J, Koikkalainen J, Tsolaki M, Mecocci P, Kloszewska I, Vellas B, Lovestone S, Visser PJ, Lötjonen J, Soininen H; Alzheimer Disease Neuroimaging Initiative; AddNeuroMed consortium; DESCRIPA and Kuopio L-MCI.

J Alzheimers Dis. 2015;44(1):79-92. doi: 10.3233/JAD-140942.

PMID:
25201784
16.

Injury markers predict time to dementia in subjects with MCI and amyloid pathology.

van Rossum IA, Vos SJ, Burns L, Knol DL, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, L'italien G, van der Flier WM, Teunissen CE, Blennow K, Barkhof F, Rueckert D, Wolz R, Verhey F, Visser PJ.

Neurology. 2012 Oct 23;79(17):1809-16. doi: 10.1212/WNL.0b013e3182704056. Epub 2012 Sep 26.

17.

Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.

van Rossum IA, Visser PJ, Knol DL, van der Flier WM, Teunissen CE, Barkhof F, Blankenstein MA, Scheltens P.

J Alzheimers Dis. 2012;29(2):319-27. doi: 10.3233/JAD-2011-111694.

PMID:
22233766
18.

Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.

Egli SC, Hirni DI, Taylor KI, Berres M, Regeniter A, Gass A, Monsch AU, Sollberger M.

J Alzheimers Dis. 2015;44(2):625-33. doi: 10.3233/JAD-141716.

PMID:
25322924
19.

Characterizing Aging, Mild Cognitive Impairment, and Dementia with Blood-Based Biomarkers and Neuropsychology.

Kleinschmidt M, Schoenfeld R, Göttlich C, Bittner D, Metzner JE, Leplow B, Demuth HU.

J Alzheimers Dis. 2016;50(1):111-26. doi: 10.3233/JAD-143189.

PMID:
26639953
20.

Cognitive, genetic, and brain perfusion factors associated with four year incidence of Alzheimer's disease from mild cognitive impairment.

Alegret M, Cuberas-Borrós G, Espinosa A, Valero S, Hernández I, Ruíz A, Becker JT, Rosende-Roca M, Mauleón A, Sotolongo O, Castell-Conesa J, Roca I, Tárraga L, Boada M.

J Alzheimers Dis. 2014;41(3):739-48. doi: 10.3233/JAD-132516.

Supplemental Content

Support Center